July 24th 2024
Following rare CRS and ICANS incidence following CAR T-cell therapy, investigators propose a reduced 2-week monitoring period with extensions as needed.
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Consideration Factors in Treatment Selection for BTKi Therapy in R/R CLL
January 31st 2024A panel of oncology experts offer insights into key consideration factors for BTKi selection for CLL in the relapsed and refractory setting, exploring the impact of emerging MAIC data on treatment decision making.
2-Min Drill: ASH 2023 Data in Multiple Myeloma Slated for FDA Approval
January 5th 2024Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to discuss data from the conference that are most likely to lead to an FDA approval.
Axatilimab Induces Rapid and Durable Responses, Is Safe in Recurrent/Refractory cGVHD
December 11th 2023Phase 2 results showed that the investigational monoclonal antibody axatilimab elicited encouraging clinical activity and tolerability across dose levels in patients with recurrent or refractory chronic graft-vs-host disease.
Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS
December 11th 2023Retrospective, real-world results showed that oral decitabine and cedazuridine and standard parenteral hypomethylating agents demonstrated similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.